The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers
Samsung Biologics will continue supplying products previously manufactured at the site to GSK
The CDMO Leadership Awards spotlight top-performing development and manufacturing service providers
The planned facility, to be built at Samsung’s Bio Campus II, is set to become a launchpad for up to 30 emerging biotech firms
Samsung Health users can now order medicines, book lab tests and online consultations through PharmEasy, along with 6 months of complimentary PharmEasy Plus membership
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed
Subscribe To Our Newsletter & Stay Updated
